World's Best Scientists 2026 revealed!
Patrick J. Loehrer

Patrick J. Loehrer

D-Index & Metrics

Medicine

D-Index
101
Citations
37928
World Ranking
7971
National Ranking
4146

Patrick J. Loehrer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Patrick J. Loehrer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 500 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Patrick J. Loehrer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Patrick J. Loehrer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 101 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Patrick J. Loehrer is affiliated with Indiana University in the United States and specializes primarily in Medicine, with a significant focus on Oncology. Their research portfolio includes 168 publications within the broader medical field, and their work spans several related subfields including Oncology, Neurology, Epidemiology, Public Health, Environmental and Occupational Health, and Surgery.

The main topics of Loehrer's research cover a range of cancer-related and medical conditions including:

  • Myasthenia Gravis and Thymoma
  • Cervical Cancer and HPV Research
  • Global Cancer Incidence and Screening
  • Pituitary Gland Disorders and Treatments
  • Economic and Financial Impacts of Cancer
  • Advances in Oncology and Radiotherapy
  • Hepatitis B Virus Studies

Loehrer has contributed to a number of recent academic papers that highlight their diverse research interests. Notable recent publications include:

  • Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC), 2021, Journal of Clinical Oncology
  • Acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer: Results of a pilot randomized trial, 2022, Palliative Medicine
  • Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency, 2024, New England Journal of Medicine
  • COVID-19, Social Justice, and Clinical Cancer Research, 2020, JNCI Journal of the National Cancer Institute
  • Recommendations from the ASCO Academic Global Oncology Task Force, 2020, JCO Global Oncology

The scientist frequently publishes in leading medical journals. The venues where Loehrer has multiple publications include:

  • Journal of Clinical Oncology
  • JCO Global Oncology
  • Proceedings of IMPRS
  • Mediastinum
  • SSRN Electronic Journal

Among coauthors, Loehrer has collaborated extensively with colleagues such as Omenge Orang'o, Kapten Muthoka, Aaron Ermel, Darron R. Brown, and Rohan Maniar, with coauthoring counts ranging from 15 to 23 joint works each.

Loehrer has also contributed to the academic literature through book publications. One such work is titled Thymoma and Thymic Carcinoma: Diagnostic Imaging, Pathological Assessment, and Treatment Options, published in 2023 by Frontiers Media.

Best Publications

  • Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

    Leonard B. Saltz;Neal J. Meropol;Patrick J. Loehrer;Michael N. Needle

  • Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide

    S D Williams;S D Williams;R Birch;R Birch;L H Einhorn;L Irwin;L Irwin

  • A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    P J Loehrer;L H Einhorn;P J Elson;E D Crawford

  • Drugs five years later. Cisplatin.

    Patrick Loehrer;Lawrence Einhorn

  • Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

    Mario A. Eisenberger;Brent A. Blumenstein;E. David Crawford;Gary Miller

  • Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner

  • Pain and Treatment of Pain in Minority Patients with Cancer: The Eastern Cooperative Oncology Group Minority Outpatient Pain Study

    Charles S. Cleeland;René Gonin;Luis Baez;Patrick Loehrer

  • Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    S B Saxman;K J Propert;L H Einhorn;E D Crawford

  • Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

    Patrick J. Loehrer;René Gonin;Craig R. Nichols;Tess Weathers

  • Pancreaticoduodenectomy: A 20-year experience in 516 patients

    C. Max Schmidt;Emilie S. Powell;Constantin T. Yiannoutsos;Thomas J. Howard

  • Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.

    L H Einhorn;S D Williams;P J Loehrer;R Birch

  • The development of non-germ cell malignancies within germ cell tumors : a clinicopathologic study of 11 cases

    Thomas M. Ulbright;Patrick J. Loehrer;Lawrence M. Roth;Lawrence H. Einhorn

  • Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

    C R Nichols;G Tricot;S D Williams;K van Besien

  • Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

    Bruce J. Roth;Robert Dreicer;Lawrence H. Einhorn;Donna Neuberg

  • Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

    C R Nichols;P J Catalano;E D Crawford;N J Vogelzang

  • Thymoma: State of the Art

    Charles R. Thomas;Cameron D. Wright;Patrick J. Loehrer

  • Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

    Patrick J. Loehrer;Kyungmann Kim;Seena C. Aisner;Robert Livingston

  • National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002

    Sidney Cohen;Bruce R. Bacon;Jesse A. Berlin;David Fleischer

  • Salvage Therapy in Recurrent Germ Cell Cancer: Ifosfamide and Cisplatin plus Either Vinblastine or Etoposide

    Patrick J. Loehrer;Richard Lauer;Bruce J. Roth;Stephen D. Williams

  • Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma

    Robert J. Motzer;Barbara A. Murphy;Jennifer Bacik;Lawrence H. Schwartz

Frequent Co-Authors

Lawrence H. Einhorn
Lawrence H. Einhorn Indiana University
Sunil Badve
Sunil Badve Emory University
Heather A. Wakelee
Heather A. Wakelee Stanford University
Thomas M. Ulbright
Thomas M. Ulbright Indiana University
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Frank C. Detterbeck
Frank C. Detterbeck Yale University
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute
Constantin T. Yiannoutsos
Constantin T. Yiannoutsos Indiana University – Purdue University Indianapolis
Kathy D. Miller
Kathy D. Miller Indiana University
George W. Sledge
George W. Sledge Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of healthcare careers, both clinical and non-clinical. For those interested in administrative roles, medical billing and coding schools online offer flexible options to kickstart a healthcare support career, often with financial aid options available.

If you’re considering nursing, some programs offer easier entry points; for example, you may be wondering, do you have to take a teas test for lpn? Many schools are now removing standardized test requirements, making it easier than ever to begin your nursing journey.

For those seeking leadership opportunities, a health administration degree can be earned entirely online and at an accelerated pace—perfect for busy professionals aiming to move into management or executive roles in the healthcare sector.

Current registered nurses holding an associate’s degree can also advance their careers via asn to np programs, providing a streamlined bridge to achieve Nurse Practitioner status.

Best Scientists Citing Patrick J. Loehrer

Trending Scientists

Recently Published Articles